Fetuin-A and change in body composition in older persons.

CONTEXT Fetuin-A inhibits the insulin receptor in vitro. Higher serum fetuin-A concentrations are associated with type 2 diabetes longitudinally and greater adiposity in cross-sectional analyses. Whether higher fetuin-A concentrations are associated with accumulation of adiposity over time is unknown. OBJECTIVE To determine the association of fetuin-A levels with changes in body composition over 5 yr. STUDY DESIGN Observational cohort study nested in the Health Aging and Body Composition Study. PREDICTOR Serum fetuin-A levels. OUTCOMES Visceral adipose tissue (VAT), abdominal sc adipose tissue, and thigh muscle area by computed tomography, and waist circumference and body mass index were measured at baseline and again after 5 yr. Percent change and extreme change (>1.5 sds) in each measure were calculated. RESULTS Over 5 yr, subjects lost body mass in each measure, including 6% decline in VAT. Yet each sd (0.42 g/liter) higher fetuin-A concentration was associated with a 5.5% increase in VAT over 5 yr (95% confidence interval 1.9-9.2%; P = 0.003) in models adjusted for age, sex, race, clinical site, diabetes, physical activity, triglycerides, kidney function, and the baseline VAT score. Similarly, higher fetuin-A concentrations were associated with extreme VAT gain (relative risk 1.70, 95% confidence interval 1.12-2.60, P = 0.01). Fetuin-A concentrations were not statistically significant associated with change in any other measures of body composition (P > 0.20). CONCLUSIONS Higher fetuin-A concentrations are associated with the accumulation of VAT in well-functioning, community-living older persons. The mechanisms linking fetuin-A, VAT, and insulin resistance remain to be determined.

[1]  M. Schulze,et al.  Plasma Fetuin-A Levels and the Risk of Myocardial Infarction and Ischemic Stroke , 2008, Circulation.

[2]  M. Schulze,et al.  Plasma Fetuin-A Levels and the Risk of Type 2 Diabetes , 2008, Diabetes.

[3]  H. Koyama,et al.  Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. , 2008, Metabolism: clinical and experimental.

[4]  Annemarie Koster,et al.  Fetuin-A and incident diabetes mellitus in older persons. , 2008, JAMA.

[5]  L. Cassis,et al.  Local adipose tissue renin-angiotensin system , 2008, Current hypertension reports.

[6]  N. Stefan,et al.  Fetuin-A Induces Cytokine Expression and Suppresses Adiponectin Production , 2008, PloS one.

[7]  G. Montalescot,et al.  Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. , 2007, Clinical chemistry.

[8]  G. Grunberger,et al.  Fetuin-null mice are protected against obesity and insulin resistance associated with aging. , 2006, Biochemical and biophysical research communications.

[9]  O. Hamdy,et al.  Metabolic obesity: the paradox between visceral and subcutaneous fat. , 2006, Current diabetes reviews.

[10]  M. Shlipak,et al.  Association Between Human Fetuin-A and the Metabolic Syndrome: Data From the Heart and Soul Study , 2006, Circulation.

[11]  F. Schick,et al.  α2-Heremans-Schmid Glycoprotein/ Fetuin-A Is Associated With Insulin Resistance and Fat Accumulation in the Liver in Humans , 2006 .

[12]  S. Cummings,et al.  Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. , 2006, Archives of internal medicine.

[13]  Z. Hochberg,et al.  Hypothalamic Regulation of Adiposity: The Role of 11β-Hydroxysteroid Dehydrogenase Type 1 , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[14]  S. Cummings,et al.  Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. , 2004, Diabetes care.

[15]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[16]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2000. , 2002, JAMA.

[17]  G. Grunberger,et al.  Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. , 2002, Diabetes.

[18]  L. Kuller,et al.  Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology. , 2002, Circulation.

[19]  C. Lamendola,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors. , 2002, Circulation.

[20]  S. Heymsfield,et al.  Weight stability masks sarcopenia in elderly men and women. , 2000, American journal of physiology. Endocrinology and metabolism.

[21]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[22]  P. Arnaud,et al.  Human Recombinant Alpha2-HS Glycoprotein is Produced in Insect Cells as a Full Length Inhibitor of the Insulin Receptor Tyrosine Kinase , 1998 .

[23]  M. Haasemann,et al.  The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. , 1992, European journal of biochemistry.

[24]  M. Haasemann,et al.  Rat tyrosine kinase inhibitor shows sequence similarity to human alpha 2-HS glycoprotein and bovine fetuin. , 1991, The Biochemical journal.

[25]  A. Cayatte,et al.  Marked acceleration of exogenous fatty acid incorporation into cellular triglycerides by fetuin. , 1990, The Journal of biological chemistry.

[26]  G. Pagès,et al.  Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity , 1989, Cell.

[27]  G. Borkan,et al.  Comparison of body composition in middle-aged and elderly males using computed tomography. , 1985, American journal of physical anthropology.

[28]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.